Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shaokun Shu(Peking University), Kornélia Polyák(Dana-Farber Cancer Institute), Melissa Duarte(Dana-Farber Cancer Institute), Prakash K. Rao(Dana-Farber Cancer Institute), Clifford A. Meyer(Dana-Farber Cancer Institute), Doris P. Tabassum(Dana-Farber Cancer Institute), Lars Anders(Pfizer (United States)), Charles Y. Lin(Kronos Bios (United Kingdom)), Ian E. Krop(Yale Cancer Center), Myles Brown(Harvard University), Michael R. McKeown(Howard Hughes Medical Institute), Justin M. Roberts(Dana-Farber Cancer Institute), Guillermo Peluffo(Harvard University), X. Shirley Liu(Harbin Medical University), Daniel G. Stover(Harvard University), Housheng Hansen He(University Health Network), Robert M. Witwicki(Dana-Farber Cancer Institute), Muhammad B. Ekram(Brigham and Women's Hospital), Jeremy Ryan(Dana-Farber Cancer Institute), Michalina Janiszewska(Scripps Research Institute), Deborah Dillon(Harvard University), Henry W. Long(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), Hao Guo(Cancer Research And Biostatistics), Jun Qi(Georgia Institute of Technology), Ernest Doherty(Harvard University Press), Min Ni(Weifang Medical University), Jason S. Carroll(Cancer Research UK Cambridge Center), Yi Liang(Jimei University), Jonathan D. Brown(Vanderbilt University), Clive S. D’Santos(University of Cambridge), Sung Jin Huh(Harvard University Press), Christopher J. Ott(Broad Institute), James E. Bradner(Novartis (China)), Shwu-Yuan Wu(The University of Texas Southwestern Medical Center), William T. Barry(Harvard University), Antony Letai(Brigham and Women's Hospital), Richard A. Young(Whitehead Institute for Biomedical Research), Cheng-Ming Chiang(The University of Texas Southwestern Medical Center), Hisham Mohammed(University of Cambridge)
Nature
January 1, 2016
Cited by 629


Related Papers